Plain-English translation of NCT06754852 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called HMB-002 designed to help people with von Willebrand disease, a bleeding disorder where the body doesn't make enough of a protein needed for blood clotting. The study will check whether the medication is safe, how the body processes it, and whether it reduces bleeding episodes. Researchers will enroll about 108 participants across three phases of testing.
Von Willebrand disease causes frequent, sometimes unpredictable bleeding that affects quality of life and requires ongoing treatment. This medication is being developed to offer a new way to help control bleeding and potentially reduce how often people need factor concentrates or other treatments.
You likely qualify if…
You likely don't qualify if…
Depending on which part of the study you join, you will either receive a single dose of the medication, multiple doses over time, or a single dose combined with your regular factor concentrate treatment. You'll attend multiple clinic visits for blood tests, vital signs, and check-ins to monitor for side effects and how well the treatment is working. The study will track your bleeding episodes and measure clotting proteins in your blood to see if the medication helps.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States